Pages

Look Towards A New Future

Mar 10, 2012

Treatment Algorithms: Alzheimer's Disease – Off-label prescribing driven by dearth of treatment options

The use of combination therapy increases at second line and in more severe patients. In the US, combination therapy is apparent even at first-line treatment of moderate and severe Alzheimer’s disease, indicating that neurologists are willing to initiate therapy of an advanced patient with a cholinesterase inhibitor and memantine.

Your key questions answered
·         How does each drug’s patient share vary by disease severity and line of therapy?
·         What can be done to influence the patient pathway to increase market share?
·         What is the realistic patient population that a new market entrant can target?
·         How has generic donepezil affected prescribing behaviors in the US?

Request a Sample for or Inquire before buying the report@

Alzheimer's Disease


Features and benefits
·         Quantify the prevalent, diagnosed, and treated Alzheimer’s disease patient populations in each of the seven major markets.
·         Analyze physician prescribing habits by disease severity and line of therapy.
·         Understand how treatment and compliance rates vary according to disease severity.
·         Identify opportunities for increasing market share through effective product positioning.

Major points covered in Table of Contents of this report include:
Executive summary
COUNTRY TREATMENT TREES
DISEASE DEFINITION AND DIAGNOSIS
PATIENT SEGMENTATION
CURRENT TREATMENT OPTIONS
BIBLIOGRAPHY

See More Healthcare Market Research Reports

Report Details :
Published:   March 2012
No. of Pages:  
Price:    Single User License - US $ 7600
                Corporate user License- US $ 19000